IP Library Granted Patent US 10,894,815
Granted Patent B2
US 10,894,815 · App. 14/429,750 · Granted Jan 19, 2021

Compositions and methods for treating heart failure in diabetic patients

Inventor: Mingdong Zhou (Shanghai, CN)
Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
C07K14/4756A61K38/1883
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,894,815
App. No.
14/429,750
Granted
Jan 19, 2021
Kind
B2
Abstract

The present invention provides the use of neuregulin protein for the preparation of medication for preventing, treating or delaying heart failure in humans and methods for preventing, treating or delaying heart failure in humans using said medication.

Claims (9)

1. A method of treating cardiac complications in a human diabetic patient, comprising administering a pharmaceutical composition comprising an effective amount of neuregulin to the patient, wherein the neuregulin comprises SEQ ID NO: 1.

2. The method of claim 1 , wherein the cardiac complication is heart failure.

3. The method of claim 1 , wherein the neuregulin is neuregulin-1, and wherein the neuregulin-1 comprises SEQ ID NO: 1.

4. The method of claim 1 , wherein the neuregulin consists of SEQ ID NO: 1.

5. The method of claim 1 , wherein the pharmaceutical composition is administered to the patient intravenously or subcutaneously.

6. The method of claim 1 , wherein the pharmaceutical composition is administered to the patient for an introduction regimen.

7. The method of claim 6 , wherein the introduction regimen includes continuous administration of the pharmaceutical composition for at least 3, 5, 7 or 10 days.

8. The method of claim 6 , wherein the pharmaceutical composition is administered to the patient for a maintenance regimen after the introduction regimen.

9. The method of claim 8 , wherein the maintenance regimen includes an administration of the pharmaceutical composition every 3, 5, 7 or 10 days.

Assignments (2)
CHANGE OF NAME Recorded Jun 8, 2016
From: ZENSUN (SHANGHAI) SCIENCE & TECHNOLOGY, LTD.
To: ZENSUN (SHANGHAI) SCIENCE & TECHNOLOGY, CO., LTD.
Reel/Frame 038925/0398 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2015
From: ZHOU, MINGDONG
To: ZENSUN (SHANGHAI) SCIENCE & TECHNOLOGY LIMITED
Reel/Frame 036308/0604 →
Continuity (1)
Related Publication 20150284440A1 · Oct 8, 2015
Cited By (1)
US 12,697,371